SCHEMBL4007049

SCHEMBL4007049

COC(=O)/C(=C\C(=O)O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 5/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 4/20 0.42
LMNA P02545 3/20 0.42
GAA P10253 1/20 0.42
SRC P12931 1/20 0.42
AKR1C1 Q04828 1/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
RECQL P46063 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007052 1.00 TSHR (0.50) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
Methane SCHEMBL534895 0.98 TSHR (0.48) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL77733 0.87 TSHR (0.48) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL6394005 0.87 TSHR (0.48) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL4732473 0.87 NFE2L2 (0.52) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL3681269 0.87 TSHR (0.48) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL1983412 0.85 ALDH1A1 (0.60) KDM4ESMN1; SMN2TDP1ALDH1A1HPGD
SCHEMBL2048794 0.84 TSHR (0.54) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL4013088 0.84 TSHR (0.54) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1
SCHEMBL210320 0.84 AKR1C1 (0.44) TSHRKDM4ESMN1; SMN2TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781617-A4 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
EP-1781617-A2 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP disclosed
WO-2006004742-A2 α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARAMCEUTICA N.V. (BE) 2006-01-12 WO disclosed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed
US-4130710-A POLYOLEFIN STABILIZERS CIBA-GEIGY CORPORATION (US) 1978-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 TSHR 301/4885KDM4E 4599/4885SMN1; SMN2 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.